研究業績

任意団体JBCRG論文・出版

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy


Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani, Young-Hyuck Im, Eun-Sook Lee, Isao Yokota, Katsumasa Kuroi, Seock-Ah Im, Byeong-Woo Park, Sung-Bae Kim, Yasuhiro Yanagita, Shinji Ohno, Shintaro Takao, Kenjiro Aogi, Hiroji Iwata, Joon Jeong, Aeree Kim, Kyong-Hwa Park, Hironobu Sasano, Yasuo Ohashi, and Masakazu Toi.


The New England Journal of Medicine 2017; 376:2147-2159 June 1, 2017DOI: 10.1056/NEJMoa1612645

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy


Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani, Young-Hyuck Im, Eun-Sook Lee, Isao Yokota, Katsumasa Kuroi, Seock-Ah Im, Byeong-Woo Park, Sung-Bae Kim, Yasuhiro Yanagita, Shinji Ohno, Shintaro Takao, Kenjiro Aogi, Hiroji Iwata, Joon Jeong, Aeree Kim, Kyong-Hwa Park, Hironobu Sasano, Yasuo Ohashi, and Masakazu Toi.


The New England Journal of Medicine 2017; 376:2147-2159 June 1, 2017DOI: 10.1056/NEJMoa1612645

Prognostic significance of subtype and pathologic response in operable breast cancer: a pooled analysis of prospective neoadjuvant studies of JBCRG


Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F.


Breast Cancer (2015) 22:486-495

Comparison of different definitions of pathologic complete response in operable breast cancer; a pooled analysis of three prospective neoadjuvant studies of JBCRG


Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F.


Breast Cancer 2015 Nov;22(6):586-95.

Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer.


Kuroi K,. Toi M, Tsuda H, Kurosumi M, Akiyama F; Japan Breast Cancer Research Group (JBCRG).


Biomed Pharmacother. 2005 Oct;59 Suppl 2:S387-92.

病理学的完全奏効ypT0/isypN0の臨床的意義 ‐JBCRG-01,JBCRG-02,JBCRG-03のプール化解析-


黒井克昌、戸井雅和、大野真司、中村清吾、岩田広治、増田慎三、佐藤信昭、津田 均、黒住昌史、秋山 太


乳癌の臨床 Vol.28 No.6 2013

Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy for Patients With Primary Breast Cancer


岩田広治、佐藤信昭、増田慎三、中村清吾、山本尚人、黒井克昌、黒住昌史、津田 均、秋山 太、大橋靖雄、戸井雅和


Japanese Journal of Clinical Oncology 41: 867-875, 2011

CREATE-X (JBCRG-04) 試験.


増田慎三


Cancer Board乳癌 2(1) 70, 2009.

PhaseII study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival


Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, YamazakiK, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F,Ohashi Y, Takatsuka Y; for Japan Breast Cancer Research Group (JBCRG)


Breast Cancer Res Treat. 2008 Aug;110(3):531-9. Epub 2007 Sep 19

原発乳癌に対するFEC followed by docetaxel 100mg/m2併用療法による術前化学療法の検討 -JBCRG02-


中村 清吾、増田 慎三、岩田 広治、戸井 雅和、黒井 克昌、黒住 昌史、津田 均、秋山 太; Japan Breast Cancer Research Group (JBCRG).


乳癌の臨床 23(2):111-117, 2008

次のページへ
一般社団法人JBCRGへ戻る